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SIRS, Thank you for the commentary on our article
which showed, for the ﬁrst time, a large inverse associa-
tion between higher dietary intakes of the dietary n-3
polyunsaturated fatty acid docosahexaenoic acid (DHA)
and incident Crohn’s disease (CD) using data from a
prospective cohort study.1, 2
Our study design is important in nutritional epidemi-
ological work as it removes both recall and selection
biases inherent in retrospective case–control studies.
Only one other similar prospective investigation exists in
this area, the US Nurses’ Health Study, which identiﬁed
269 incident cases and did not report any associations
with total long-chain n-3 PUFA intake and CD.3 This
investigation was very well conducted with large num-
bers of participants and several assessments of habitual
diet, but did not speciﬁcally report DHA intake. As indi-
vidual n-3 PUFAs may have differing effects on the
inﬂammatory process, this may explain the discrepancies
between the results from the two cohorts.
Our ﬁndings are unlikely to be due to recall bias, as
all participants were well at recruitment and their diet
would not be affected by symptoms. Although in our
work, more than one measure of diet would have been
preferable, any changes over time would result in spuri-
ous under-estimates of effect sizes, rather than false
over-estimates. Ideally, other cohort studies are required
to investigate DHA, in the aetiology of CD, although we
are unaware of any.
An approach to help clarify the effect of DHA is to
conduct clinical trials of purely DHA supplementation,
as opposed to ﬁsh oils in previous studies, in the treat-
ment of CD. Whether the potential effects of DHA are
similar in aetiology and on clinical parameters is
unknown. However, our epidemiological work would
support the further investigation of DHA as a chemopre-
ventive and possibly a treatment option for CD.
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